Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Ramos

Showing results (541-550 of 606) with videos related to

Pageof 61
Sort By:
Experimental Parasitology|May 29, 2023
In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasisCamila S Freitas, Samira S Santiago, Daniela P Lage, et al.
Diagnostic Microbiology and Infectious Disease|June 4, 2019
Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controlsDanniele L Vale, Daniel S Dias, Amanda S Machado, et al.
Biology|June 28, 2023
Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral LeishmaniasisDanniele L Vale, Camila S Freitas, Vívian T Martins, et al.
Immunobiology|October 28, 2017
Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasisÁquila S B Portela, Lourena E Costa, Beatriz C S Salles, et al.
Cytokine|February 12, 2023
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasisCamila S Freitas, Daniela P Lage, Amanda S Machado, et al.
Vaccines|June 13, 2020
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral LeishmaniasisDaniela P Lage, Patrícia A F Ribeiro, Daniel S Dias, et al.
Immunobiology|September 30, 2018
Potential application of small myristoylated protein-3 evaluated as recombinant antigen and a synthetic peptide containing its linear B-cell epitope for the serodiagnosis of canine visceral and human tegumentary leishmaniasisBeatriz C S Salles, Daniel S Dias, Bethina T Steiner, et al.
Experimental Parasitology|December 18, 2020
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasisThiago A R Reis, João A Oliveira-da-Silva, Grasiele S V Tavares, et al.
Parasitology Research|September 28, 2023
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasisMarcelo M Jesus, Daniela P Lage, Danniele L Vale, et al.
Acta Tropica|March 20, 2022
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantumAmanda S Machado, Daniela P Lage, Danniele L Vale, et al.
Pageof 61

Showing results (541-550 of 606) with videos related to

Sort By:
Pageof 61
Experimental Parasitology|May 29, 2023
In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasisCamila S Freitas, Samira S Santiago, Daniela P Lage, et al.
Diagnostic Microbiology and Infectious Disease|June 4, 2019
Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controlsDanniele L Vale, Daniel S Dias, Amanda S Machado, et al.
Biology|June 28, 2023
Efficacy of an Immunotherapy Combining Immunogenic Chimeric Protein Plus Adjuvant and Amphotericin B against Murine Visceral LeishmaniasisDanniele L Vale, Camila S Freitas, Vívian T Martins, et al.
Immunobiology|October 28, 2017
Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasisÁquila S B Portela, Lourena E Costa, Beatriz C S Salles, et al.
Cytokine|February 12, 2023
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasisCamila S Freitas, Daniela P Lage, Amanda S Machado, et al.
Vaccines|June 13, 2020
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral LeishmaniasisDaniela P Lage, Patrícia A F Ribeiro, Daniel S Dias, et al.
Immunobiology|September 30, 2018
Potential application of small myristoylated protein-3 evaluated as recombinant antigen and a synthetic peptide containing its linear B-cell epitope for the serodiagnosis of canine visceral and human tegumentary leishmaniasisBeatriz C S Salles, Daniel S Dias, Bethina T Steiner, et al.
Experimental Parasitology|December 18, 2020
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasisThiago A R Reis, João A Oliveira-da-Silva, Grasiele S V Tavares, et al.
Parasitology Research|September 28, 2023
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasisMarcelo M Jesus, Daniela P Lage, Danniele L Vale, et al.
Acta Tropica|March 20, 2022
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantumAmanda S Machado, Daniela P Lage, Danniele L Vale, et al.
Pageof 61